±¹³»µµ¼
Àü°øµµ¼/´ëÇб³Àç
ÀǾàÇа£È£°è¿
2013³â 9¿ù 9ÀÏ ÀÌÈÄ ´©Àû¼öÄ¡ÀÔ´Ï´Ù.
Á¤°¡ |
60,000¿ø |
---|
54,000¿ø (10%ÇÒÀÎ)
3,000P (5%Àû¸³)
ÇÒÀÎÇýÅÃ | |
---|---|
Àû¸³ÇýÅà |
|
|
|
Ãß°¡ÇýÅÃ |
|
À̺¥Æ®/±âȹÀü
¿¬°üµµ¼
»óÇ°±Ç
ÀÌ»óÇ°ÀÇ ºÐ·ù
Ã¥¼Ò°³
Á¦¾à¾÷°è À¯ÀÏÀÇ ¿µ¹® °¡ÀÌµå ºÏ
¿µ¹® °¡ÀÌµå ºÏÀ¸·Î ¸Å³â Á¦À۵ǰí ÀÖ´Â 'Æĸ¶½´Æ¼Äýº ÀÎ ÄÚ¸®¾Æ'´Â ±¹³» Á¦¾à»ê¾÷ºÎÅÍ ÀÇ·á°è, Á¦µµ¡¤Á¤Ã¥, ¿¬±¸¡¤°³¹ß, ½ÃÀ嵿Ç⠵ À̸£±â±îÁö ÃÖ½ÅÁ¤º¸¸¦ Æø³Ð°Ô Á¦°øÇÏ°í ÀÖ½À´Ï´Ù. 2016³âÆÇÀÇ °æ¿ì ¾ö¼±µÈ ÁÖ¿ä ±¹³» Á¦¾à±â¾÷ ¹× »ý¸í°øÇбâ¾÷µéÀÇ °³¿ä¸¦ ¼Ò»óÇÏ°Ô ¼³¸íÇϱâ À§ÇØ º°µµÀÇ ¼½¼ÇÀ» ¸¶·Ã Çß½À´Ï´Ù. ÀÌ¿Í ÇÔ²² Çѱ¹ÀǾàǪ¹«ÃâÀÔÇùȸ(KPTA)ÀÇ Àüü ȸ¿ø»ç ¸®½ºÆ®µµ ¼ö·ÏµÇ¾î ÀÖ½À´Ï´Ù.
ÃâÆÇ»ç ¼Æò
'Æĸ¶½´Æ¼Äýº ÀÎ ÄÚ¸®¾Æ'(Pharmaceuticals in Korea) 2016³âÆÇ
- Á¦¾à¾÷°è À¯ÀÏÀÇ ¿µ¹® °¡ÀÌµå ºÏ
- ±¹³» Á¦¾à»ê¾÷¿¡ ´ëÇØ Æ÷°ýÀûÀÌ¸é¼ ÃÖ½ÅÀÇ Á¤º¸ ¹× ÀÚ·á ¼ö·Ï
- ÁÖ¿ä ±¹³» Á¦¾à/»ý¸í°øÇбâ¾÷µéÀÇ °³¿ä¿Í ÇÙ½ÉÁ¦Ç° ¼Ò°³
¾à¾÷½Å¹®Àº 2016³âÆÇ 'Æĸ¶½´Æ¼Äýº ÀÎ ÄÚ¸®¾Æ(Pharmaceuticals in Korea)'¸¦ ¹ß°£ Çß½À´Ï´Ù.
¿µ¹® °¡ÀÌµå ºÏÀ¸·Î ¸Å³â Á¦À۵ǰí ÀÖ´Â 'Æĸ¶½´Æ¼Äýº ÀÎ ÄÚ¸®¾Æ'´Â ±¹³» Á¦¾à»ê¾÷ºÎÅÍ ÀÇ·á°è, Á¦µµ¡¤Á¤Ã¥, ¿¬±¸¡¤°³¹ß, ½ÃÀ嵿Ç⠵ À̸£±â±îÁö ÃÖ½ÅÁ¤º¸¸¦ Æø³Ð°Ô Á¦°øÇÏ°í ÀÖ½À´Ï´Ù. 2016³âÆÇÀÇ °æ¿ì ¾ö¼±µÈ ÁÖ¿ä ±¹³» Á¦¾à±â¾÷ ¹× »ý¸í°øÇбâ¾÷µéÀÇ °³¿ä¸¦ ¼Ò»óÇÏ°Ô ¼³¸íÇϱâ À§ÇØ º°µµÀÇ ¼½¼ÇÀ» ¸¶·Ã Çß½À´Ï´Ù.
ÀÌ¿Í ÇÔ²² Çѱ¹ÀǾàǪ¹«ÃâÀÔÇùȸ(KPTA)ÀÇ Àüü ȸ¿ø»ç ¸®½ºÆ®µµ ¼ö·ÏµÇ¾î ÀÖ½À´Ï´Ù.
¸ñÂ÷
CHAPTER 1. PHARMACEUTICAL & DISTRIBUTION INDUSTRY
PART 1: PHARMACEUTICAL INDUSTRY OVERIEW
1) PHARMACEUTICAL MARKET TREND | 10
A) DOMESTIC PHARMACEUTICAL MARKET SIZE | 10
B) ACTIVE PHARMACEUTICAL INGREDIENT/FINISHED DRUG MANUFACTURING PERFORMANCE | 12
C) OTC/ETC DRUG MANUFACTURING PERFORMANCE | 13
D) MANUFACTURING PERFORMANCE BY THERAPEUTIC CATEGORY | 13
E) FINISHED DRUG MANUFACTURING PERFORMANCE BY PHARMACEUTICAL COMPANY | 14
F) MANUFACTURING PERFORMANCE BY MAIN PRODUCTS | 16
G) DOMESTIC NEW DRUG MANUFACTURING PERFORMANCE | 17
H) INCREMENTALLY MODIFIED DRUG MANUFACTURING PERFORMANCE | 19
I) ORPHAN DRUG MANUFACTURING PERFORMANCE | 20
2) PHARMACEUTICAL APPROVALS | 22
A) 2014 PHARMACEUTICAL APPROVALS AND REGISTRATIONS | 22
B) 2014 NEW DRUG APPROVALS | 23
C) 2014 NEW DRUG APPROVALS BY THERAPEUTIC CATEGORY | 26
D) DOMESTIC NEW DRUG APPROVALS | 29
3) PHARMACEUTICAL IMPORT AND EXPORT | 33
A) 2014 PHARMACEUTICAL IMPORT AND EXPORT PERFORMANCE | 33
B) ANNUAL PHARMACEUTICAL IMPORT AND EXPORT PERFORMANCE | 34
C) 2014 PHARMACEUTICAL IMPORT AND EXPORT PERFORMANCE BY COUNTRY | 35
D) 2014 PHARMACEUTICAL IMPORT PERFORMANCE BY THERAPEUTIC CATEGORY | 37
E) 2014 PHARMACEUTICAL IIMPORT PERFORMANCE OF TOP COMPANIES AND PRODUCTS | 38
F) TECHNOLOGY EXPORT AND EXPORT DIVERSIFICATION | 40
G) DEPENDENCE LOW ON EXPORTS BUT HIGH ON DOMESTIC MARKET | 43
4) RESEARCH AND DEVELOPMENT | 46
A) OVERALL CONDITION OF R&D-BASED PHARMACEUTICAL COMPANIES | 46
B) NEW DRUG DEVELOPMENT REQUIRED 9.1 YEARS AND SPENT KRW 38 BILLION ON AVERAGE | 49
C) TREND OF LISTED PHARMACEUTICAL COMPANIES ENLARGING R&D EXPENSES | 51
D) "POLARIZATION" OF PHARMACEUTICAL COMAPNIES IN R&D | 53
E) INCREMENTALLY MODIFIED NEW DRUG DEVELOPMENT RESULTS | 55
F) TECHNOLOGY EXPORTS OF DOMESTIC LISTED PHARMACEUTICAL COMPANIES | 58
5) PHARMACEUTICAL ADVERTISING | 61
A) DIRECT-TO-CONSUMER PHARMACEUTICAL ADVERTISING | 61
B) TIGHTENED DELIBERATION OF OTC DRUGS DTC ADVERTISEMENT | 62
C) ADVERTISING EXPENSES OF LISTED PHARMACEUTICAL COMPANIES IN 2014 | 63
D) ADVERTISING EXPENSES OF MULTINATIONAL PHARMACEUTICAL COMPANIES IN 2014 | 65
6) MULTINATIONAL PHARMACEUTICAL COMAPNEIS ENTERED IN KOREA | 67
A) SALES AND PROFITS OF FOREIGN PHARMACEUTICAL COMAPNEIS IN 2014 | 67
B) ANNUAL SALES PER EMPLOYEE OF EACH FOREIGN PHARMACEUTICAL COMPANY | 68
C) FOREIGN PHARMACEUTICAL COMAPNIES SPENT 4.5% OF SALES IN ADVERTISING EXPENSES | 70
D) PATENT APPLICATIONS OF DOMESTIC PHARMACEUTICAL COMPANIES ACCOUNTING FOR 18% OF FOREIGN ONES | 71
7) PHARMACISTS AND PHARMACIES | 73
A) PHARMACIST LICENSE HOLDERS ACROSS THE NATION | 73
B) NARROWLY INCREASING NUMBER OF PHARMACIES | 75
C) DECREASING FREQUENCY OF UTILIZATION OF PHARMACIES | 77
D) ADOPTION OF PHARMACEUTICAL SALES SYSTEM AT THE OUTSIDE OF PHARMACIES | 78
PART 2: BIOINDUSTRY OVERVIEW
1) BIOINDUSTRIAL MARKET TREND | 80
A) BIOINDUSTRY INTRODUCTION | 80
B) MANUFACTURING SCALE OF DOMESTIC BIOINDUSTRY | 82
C) DEVELOPMENT TREND OF BIOSIMILARS | 87
2) BIOINDUSTRIAL PROMOTION | 89
A) BIOINDUSTRY POLICIES | 89
B) STRATEGY TO PROMOTE BIO-RELATED NEW INDUSTRIES | 89
C) FUTURE OF DOMESTIC BIOINDUSTRY | 91
PART 3: PHARMACEUTICAL DISTRIBUTION INDUSTRY
1) PRESENT STATE OF PHARMACEUTICAL DISTRIBUTION INDUSTRY | 93
A) INCREASING NUMBER OF PHARMACEUTICAL DISTRIBUTION COMPANIES SINCE NEW MILLENNIUM | 93
B) SUDDEN CHANGES OF PHARMACEUTICAL DISTRIBUTION ENVIRONMENT | 94
C) SECUREMENT OF REASONABLE PHARMACEUTICAL DISTRIBUTION COST | 97
2) BUSINESS PERFORMANCE OF PHARMACEUTICAL DISTRIBUTION COMPANIES | 98
A) THE RICH-GET-RICHER AND THE POOR-GET-POORER IN BUSINESS PERFORMANCE | 98
B) TOP 5% COMPANIES SUPPLYING 60% OF THE ENTIRE INDUSTRY | 102
PART 4: HEALTH FUNCTIONAL FOOD INDUSTRY
1) HEALTH FUNCTIONAL FOOD MARKET OVERVIEW | 104
A) ADOPTION OF GMP POLICY | 104
B) ENACTMENT OF THE HEALTH FUNCTIONAL FOOD ACT | 105
C) PRESENT STATE OF HEALTH FUNCTIONAL FOOD COMPANIES | 106
D) ENTRY TO KRW 1 TRILLION MARKET IN 2010 | 108
E) HEALTH FUNCTIONAL FOOD MANUFACTURING VOLUME OF KRW 1.5 TRILLION IN 2013 | 109
F) HEALTH FUNCTIONAL FOODS BY PRODUCT AND COMPANY | 110
G) HEALTH FUNCTIONAL FOOD IMPORT | 113
2) NEW TREND OF HEALTH FUNCTIONAL FOOD | 115
A) OVER 50% OF ADULTS EXPERIENCING IN PURCHASING HEALTH FUNCTIONAL FOODS | 115
B) SUPERMARKETS BECOMING THE KEY DISTRIBUTION CHANNEL FOR HEALTH FUNCTIONAL FOODS | 116
C) INCREASING CONSUMPTION OF HEALTH FUNCTIONAL FOODS AMONG YOUNG PEOPLE | 117
D) SAFETY TIGHTENING AND REGULATION RATIONALIZATION | 118
PART 5: MEDICAL EQUIPMENT INDUSTRY
1) MEDICAL EQUIPMENT MARKET OVERVIEW | 120
A) MEDICAL EQUIPMENT MANUFACTURING PERFORMANCE | 120
B) MEDICAL EQUIPMENT EXPORT OF USD 240 MILLION IN 2014 | 121
C) STRATEGY TO PROMOTE MEDICAL EQUIPMENT INDUSTRY | 123
CHAPTER 2. POLICY AND RELATED SYSTEM
PART 1: PHARMACEUTICAL INDUSTRY POLICY
1) BASIC DIRECTIN OF PHARMACEUTICAL POLICY | 126
A) "LIGHT AND SHADE" OF KOREAN PHARMACEUTICAL INDUSTRY | 126
B) ENACTMENT OF SPECIAL ACT TO SUPPORT PHARMACEUTICAL INDUSTRY | 129
C) ANNOUNCEMENT OF 'PHARMA KOREA 2020' VISION | 130
D) PROMOTION OF 12 GLOBAL PHARMACEUTICAL COMAPNIES BY 2020 | 131
E) SELECTION OF 'INNOVATIVE PHARMACEUTICAL COMPANIES' | 132
F) FIRST ESTABLISHMENT OF FUND SPECIALIZING IN PHARMACEUTICAL INDUSTRY | 134
2) KOREA-US FTA AND PHARMACEUTICAL SOVEREIGNTY PROTECTION | 135
A) ACTIVE NEGOTIATIONS OF KOREA-US FTA | 135
B) KOREA-US FTA SETTLEMENT AS A NEW TRADE RULES | 136
C) ENFORCEMENT OF 'PATENT-LINKAGE SYSTEM' | 137
PART 2: NATIONAL HEALTH INSURANCE
1) HEALTH INSURANCE SYSTEM OVERVIEW | 139
A) HEALTH INSURNACE ENROLLMENT | 140
B) HEALTH INSURANCE FEES AND BENEFITS | 141
C) MEDICAL INSTITUTIONS AND PERSONNEL | 145
D) HEALTH INSURANCE FINANCES | 147
E) EXPANDED HEALTH INSURANCE COVERAGE | 149
2) HEALTH INSURANCE PAYMENT SYSTEM | 150
A) FEE-FOR-SERVICE PAYMENT SYSTEM | 150
B) DIAGNOSIS-RELATED GROUP(DRG) PAYMENT SYSTEM ON 7 DISEASE GROUPS | 150
C) INSURANCE COVERAGE EXTENSION FOR SEVERE DISEASES | 151
3) DRUG PRICING POLICY OF NATIONAL HEALTH INSURANCE | 152
A) BACKGROUND OF DRUG PRICING POLICY REFORM | 152
B) POSITIVE LIST SYSTEM | 152
C) INCENTIVE SYSTEM FOR LOW-PRICE PURCHASE | 153
D) PACKAGE DURG PRICE REDUCTION SYSTEM | 154
E) USAGE-PRICE LINKAGE SYSTEM | 154
F) INCENTIVE SYSTEM FOR DRUG PRESCRIBING AND DISPENSING EXPENSE CUTS | 155
G) INCENTIVE SYSTEM FOR LOW-PRICE PURCHASE (MARKET-BASED ACTUAL TRANSACTION PRICE SYSTEM) | 155
H) ADOPTION OF RISK-SHARING SYSTEM | 156
I) INCENTIVE SYSTEM FOR LOW-PRICE GENERIC SUBSTITUTION | 156
PART 3: SPECIAL FEATURE
THE PRESENT AND FUTURE OF THE KOREAN PHARMACEUTICAL INDUSTRY
1) SOCIAL AND ECONOMIC CONTRIBUTION OF THE PHARMACEUTICAL INDUSTRY | 159
2) THE DOMESTIC PHARMACEUTICAL INDUSTRY¡¯S R&D INVESTMENTS AND RESULTS | 166
3) R&D PIPELINES OF THE DOMESTIC PHARMACEUTICAL INDUSTRY | 171
4) FOREIGN EXPANSION OF THE DOMESTIC PHARMACEUTICAL INDUSTRY | 173
5) PROSPECT OF THE DOMESTIC PHARMACEUTICAL INDUSTRY | 174
6) CONCLUSION | 180
Chapter 3. Pharmaceutical Corporation Introduction
Ahngook Pharm. Co., Ltd. | 182
Boryung Pharmaceutical Co., Ltd. | 190
Chong Kun Dang Pharmaceutical Corp. | 200
CL Pharm Co., Ltd. | 216
DAE HWA Pharmaceutical Co., Ltd. | 218
Daewoong Pharmaceutical Co., Ltd. | 234
Dong Wha Pharmaceutical Co., Ltd. | 246
Enzychem Lifesciences Corporation | 276
Green Cross | 280
Hanlim Pharm. Co., Ltd. | 282
Hanmi Pharm. Co., Ltd. | 302
Hyundai Pharm. Co., Ltd. | 332
Ildong Pharmaceutical Co., Ltd. | 338
JW Pharmaceutical Corporation | 350
Kolmar Korea Co., Ltd. | 366
Korea United Pharm. Inc. (KUP) | 372
Myungmoon Pharmaceutical Co., Ltd. | 386
Samjin Pharm. Co., Ltd. | 408
Tai Guk Pharm. Co., Ltd. | 426
Countec Co., Ltd. | 434
PTK Co., Ltd. | 440
Kyungyon Exhibition Corporation| 450
Chapter 4. Korea Pharmaceutical Traders Association
Membership List
KPTA Member List | 458
ÁÖ°£·©Å·
´õº¸±â»óÇ°Á¤º¸Á¦°ø°í½Ã
À̺¥Æ® ±âȹÀü
Àü°øµµ¼/´ëÇб³Àç ºÐ¾ß¿¡¼ ¸¹Àº ȸ¿øÀÌ ±¸¸ÅÇÑ Ã¥
ÆǸÅÀÚÁ¤º¸
»óÈ£ |
(ÁÖ)±³º¸¹®°í |
---|---|
´ëÇ¥ÀÚ¸í |
¾Èº´Çö |
»ç¾÷ÀÚµî·Ï¹øÈ£ |
102-81-11670 |
¿¬¶ôó |
1544-1900 |
ÀüÀÚ¿ìÆíÁÖ¼Ò |
callcenter@kyobobook.co.kr |
Åë½ÅÆǸž÷½Å°í¹øÈ£ |
01-0653 |
¿µ¾÷¼ÒÀçÁö |
¼¿ïƯº°½Ã Á¾·Î±¸ Á¾·Î 1(Á¾·Î1°¡,±³º¸ºôµù) |
±³È¯/ȯºÒ
¹ÝÇ°/±³È¯ ¹æ¹ý |
¡®¸¶ÀÌÆäÀÌÁö > Ãë¼Ò/¹ÝÇ°/±³È¯/ȯºÒ¡¯ ¿¡¼ ½Åû ¶Ç´Â 1:1 ¹®ÀÇ °Ô½ÃÆÇ ¹× °í°´¼¾ÅÍ(1577-2555)¿¡¼ ½Åû °¡´É |
---|---|
¹ÝÇ°/±³È¯°¡´É ±â°£ |
º¯½É ¹ÝÇ°ÀÇ °æ¿ì Ãâ°í¿Ï·á ÈÄ 6ÀÏ(¿µ¾÷ÀÏ ±âÁØ) À̳»±îÁö¸¸ °¡´É |
¹ÝÇ°/±³È¯ ºñ¿ë |
º¯½É ȤÀº ±¸¸ÅÂø¿À·Î ÀÎÇÑ ¹ÝÇ°/±³È¯Àº ¹Ý¼Û·á °í°´ ºÎ´ã |
¹ÝÇ°/±³È¯ ºÒ°¡ »çÀ¯ |
·¼ÒºñÀÚÀÇ Ã¥ÀÓ ÀÖ´Â »çÀ¯·Î »óÇ° µîÀÌ ¼Õ½Ç ¶Ç´Â ÈÑ¼ÕµÈ °æ¿ì ·¼ÒºñÀÚÀÇ »ç¿ë, Æ÷Àå °³ºÀ¿¡ ÀÇÇØ »óÇ° µîÀÇ °¡Ä¡°¡ ÇöÀúÈ÷ °¨¼ÒÇÑ °æ¿ì ·º¹Á¦°¡ °¡´ÉÇÑ »óÇ° µîÀÇ Æ÷ÀåÀ» ÈѼÕÇÑ °æ¿ì ·½Ã°£ÀÇ °æ°ú¿¡ ÀÇÇØ ÀçÆǸŰ¡ °ï¶õÇÑ Á¤µµ·Î °¡Ä¡°¡ ÇöÀúÈ÷ °¨¼ÒÇÑ °æ¿ì ·ÀüÀÚ»ó°Å·¡ µî¿¡¼ÀÇ ¼ÒºñÀÚº¸È£¿¡ °üÇÑ ¹ý·üÀÌ Á¤ÇÏ´Â ¼ÒºñÀÚ Ã»¾àöȸ Á¦ÇÑ ³»¿ë¿¡ ÇØ´çµÇ´Â °æ¿ì |
»óÇ° Ç°Àý |
°ø±Þ»ç(ÃâÆÇ»ç) Àç°í »çÁ¤¿¡ ÀÇÇØ Ç°Àý/Áö¿¬µÉ ¼ö ÀÖÀ½ |
¼ÒºñÀÚ ÇÇÇغ¸»ó |
·»óÇ°ÀÇ ºÒ·®¿¡ ÀÇÇÑ ±³È¯, A/S, ȯºÒ, Ç°Áúº¸Áõ ¹× ÇÇÇغ¸»ó µî¿¡ °üÇÑ »çÇ×Àº¼ÒºñÀÚºÐÀïÇØ°á ±âÁØ (°øÁ¤°Å·¡À§¿øȸ °í½Ã)¿¡ ÁØÇÏ¿© ó¸®µÊ ·´ë±Ý ȯºÒ ¹× ȯºÒÁö¿¬¿¡ µû¸¥ ¹è»ó±Ý Áö±Þ Á¶°Ç, ÀýÂ÷ µîÀº ÀüÀÚ»ó°Å·¡ µî¿¡¼ÀǼҺñÀÚ º¸È£¿¡ °üÇÑ ¹ý·ü¿¡ µû¶ó ó¸®ÇÔ |
(ÁÖ)ÀÎÅÍÆÄÅ©Ä¿¸Ó½º´Â ȸ¿ø´ÔµéÀÇ ¾ÈÀü°Å·¡¸¦ À§ÇØ ±¸¸Å±Ý¾×, °áÁ¦¼ö´Ü¿¡ »ó°ü¾øÀÌ (ÁÖ)ÀÎÅÍÆÄÅ©Ä¿¸Ó½º¸¦ ÅëÇÑ ¸ðµç °Å·¡¿¡ ´ëÇÏ¿©
(ÁÖ)KGÀ̴Ͻýº°¡ Á¦°øÇÏ´Â ±¸¸Å¾ÈÀü¼ºñ½º¸¦ Àû¿ëÇÏ°í ÀÖ½À´Ï´Ù.
¹è¼Û¾È³»
±³º¸¹®°í »óÇ°Àº Åùè·Î ¹è¼ÛµÇ¸ç, Ãâ°í¿Ï·á 1~2Àϳ» »óÇ°À» ¹Þ¾Æ º¸½Ç ¼ö ÀÖ½À´Ï´Ù.
Ãâ°í°¡´É ½Ã°£ÀÌ ¼·Î ´Ù¸¥ »óÇ°À» ÇÔ²² ÁÖ¹®ÇÒ °æ¿ì Ãâ°í°¡´É ½Ã°£ÀÌ °¡Àå ±ä »óÇ°À» ±âÁØÀ¸·Î ¹è¼ÛµË´Ï´Ù.
±ººÎ´ë, ±³µµ¼Ò µî ƯÁ¤±â°üÀº ¿ìü±¹ Åù踸 ¹è¼Û°¡´ÉÇÕ´Ï´Ù.
¹è¼Ûºñ´Â ¾÷ü ¹è¼Ûºñ Á¤Ã¥¿¡ µû¸¨´Ï´Ù.